Enlivex Therapeutics Ltd.

NASDAQ: ENLV · Real-Time Price · USD
1.82
0.04 (2.25%)
At close: Aug 15, 2025, 3:59 PM
1.91
4.95%
After-hours: Aug 15, 2025, 07:55 PM EDT

Enlivex Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
545K 835K 777K 546K
Gross Profit
-545K -835K -777K -546K
Operating Income
-15.54M -29.39M -25.8M -19.29M
Interest Income
1.07M 1.56M 835K 120K
Pretax Income
-15.01M -29.07M -31.06M -14.47M
Net Income
-15.01M -29.07M -31.06M -14.47M
Selling & General & Admin
4.87M 6.14M 6.7M 6.24M
Research & Development
10.13M 19.23M 18.69M 12.88M
Other Expenses
n/a 4.02M 402K 167K
Operating Expenses
14.99M 29.39M 25.8M 19.29M
Interest Expense
n/a 14K 5.26M 328K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
15.54M 24.93M 24.59M 18.27M
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
20.51M 18.57M 18.39M 17.86M
Shares Outstanding (Diluted)
20.51M 18.57M 18.39M 17.86M
EPS (Basic)
-0.73 -1.56 -2.31 -0.54
EPS (Diluted)
-0.73 -1.56 -2.31 -0.54
EBITDA
-14.47M -28.22M -25.02M -18.74M
EBIT
-15.01M -29.05M -25.8M -19.29M
Depreciation & Amortization
545K 835K 777K 546K